Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pramodini MedicareNSE:PRAMODINI -2.01%19 ROE % is 39.12% as of Mar. 2026, which is 12% above its 10-year median of 35.01. GuruFocus rates NSE:PRAMODINI with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 630 Healthcare Providers & Services companies, Pramodini Medicare ranks better than 64.6% on this metric.
The historical rank and industry rank for Pramodini Medicare's ROE % or its related term are showing as below:
NSE:PRAMODINI'
s ROE % Range Over the Past 10 Years
Min: 10.76 Med: 35.01 Max: 39.08
Current: 10.76
During the past 4 years, Pramodini Medicare's highest ROE % was 39.08%. The lowest was 10.76%. And the median was 35.01%.
NSE:PRAMODINI's ROE % is ranked better than 64.6% of 630
companies
in the Healthcare Providers & Services industry
Industry Median: 6.22
vs NSE:PRAMODINI: 10.76
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Pramodini Medicare ROE % Related Terms
Pramodini Medicare ROE % Historical Data
* Premium members only.
The historical data trend for Pramodini Medicare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pramodini Medicare ROE % Chart
Pramodini Medicare Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
ROE %
25.91
33.58
36.44
39.08
Pramodini Medicare Quarterly Data
Mar23
Mar24
Mar25
Dec25
Mar26
ROE %
0.00
0.00
0.00
0.00
39.12
NSE:PRAMODINI vs HCA, THC, EHC: ROE % Comparison
For the Medical Care Facilities subindustry, Pramodini Medicare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pramodini Medicare ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pramodini Medicare's ROE % distribution charts can be found below:
* The bar in red indicates where Pramodini Medicare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Pramodini Medicare (NSE:PRAMODINI) has a ROE % of 39.12% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pramodini Medicare and its competitors. This is 12% above median its historical median of 35.01. Over the past decade, Pramodini Medicare's ROE % has ranged from 10.76 to 39.08. According to the industry distribution chart, Pramodini Medicare ranks #223 out of 630 companies in the Healthcare Providers & Services industry, placing it in the top 35.4%.
Is Pramodini Medicare's ROE % too high?
Pramodini Medicare's current ROE % of 39.12% is 12% above median its 10-year median of 35.01. Over the past 10 years, this metric has ranged from a low of 10.76 to a high of 39.08. The Healthcare Providers & Services industry median ROE % is 6.22. Pramodini Medicare's value of 39.12% is 528.9% above this industry median. Based on the distribution chart, Pramodini Medicare ranks #223 out of 630 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pramodini Medicare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pramodini Medicare's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Pramodini Medicare ranks #223 out of 630 companies for ROE %. This puts Pramodini Medicare in the upper half of its industry. The industry median ROE % is 6.22. Pramodini Medicare's value of 39.12% is 528.9% above this benchmark. Historically, Pramodini Medicare's own ROE % has ranged from 10.76 to 39.08 over the past decade. While the company's 10-year median is 35.01 vs. the industry median of 6.22, Pramodini Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 6.22, based on 630 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pramodini Medicare's current ROE % of 39.12% is 528.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pramodini Medicare and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 6.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pramodini Medicare's current ROE % is 39.12%, which is 12% above median its own 10-year median of 35.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pramodini Medicare stock overvalued right now?
Pramodini Medicare (NSE:PRAMODINI) has a current ROE % of 39.12%. The current ROE % is 39.12%, which is 12% above median its 10-year median of 35.01 and 528.9% above the Healthcare Providers & Services industry median of 6.22. Pramodini Medicare's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Pramodini Medicare (NSE:PRAMODINI), the current ROE % is 39.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pramodini Medicare Ltd is a diagnostic service provider in India. It provides a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. The company also provide teleradiology services, which functions on a 24*7 basis throughout the year. It provides healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions. Its services includes both routine and specialized tests, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of diseases.
19GF Score
Get the complete analysis for NSE:PRAMODINI
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PRAMODINI has been successfully added to your 
